Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $367.00, but opened at $388.00. Genmab A/S shares last traded at $388.00, with a volume of 402 shares.
Genmab A/S Stock Performance
The company has a 50 day moving average of $346.73 and a 200 day moving average of $297.16. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a market cap of $23.92 billion, a price-to-earnings ratio of 27.81 and a beta of 0.75.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Recommended Stories
- Five stocks we like better than Genmab A/S
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
